A phase I open-label trial investigating nivolumab and DS-8201 in HER2-expressing metastatic breast and urothelial (bladder) cancers

Trial Profile

A phase I open-label trial investigating nivolumab and DS-8201 in HER2-expressing metastatic breast and urothelial (bladder) cancers

Planning
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs DS 8201 (Primary) ; Nivolumab (Primary)
  • Indications Bladder cancer; Breast cancer
  • Focus Adverse reactions
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 01 Sep 2017 New trial record
    • 28 Aug 2017 The study is expected to begin enrollment in first quarter of 2018 in the US and Europe, according to a Bristol-Myers Squibb media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top